使用警語:中文譯文來源為 Google 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2021 Prestige Consumer Healthcare, Inc.
Earnings Conference Call.
(Operator Instructions) Please be advised that today's conference is being recorded.
(Operator Instructions) I would now like to hand the conference over to your speaker today, Mr. Phil Terpolilli, Director of Investor Relations.
Thank you.
Please go ahead, sir.
Philip David Terpolilli - Director of IR
Thanks, operator, and thank you to everyone who has joined today.
On the call with me are Ron Lombardi, our Chairman, President and CEO; and Chris Sacco, our CFO.
On today's call, we'll begin with some topical remarks given the current pandemic, review the results of the first quarter of fiscal '21, provide an outlook update, and then take questions from analysts.
We have a slide presentation, which accompanies today's call that can be accessed by visiting prestigeconsumerhealthcare.com, clicking on the Investors link, and then on today's webcast and presentation.
Please remember some of the information contained in the presentation today include non-GAAP financial measures.
Reconciliations to the nearest GAAP financial measures are included in today's earnings release and slide presentation.
During today's call, management will make forward-looking statements around risks and uncertainties, which are detailed in a complete safe harbor disclosure on Page 2 of the slide presentation accompanying the call.
These are important to review and contemplate as everyone on the call today is well aware, business environment uncertainty remains heightened due to duration and impact of COVID-19.
These impacts include an uncertain shutdown time frame for many areas of our economy, ongoing changes to consumer purchasing habits, the potential for a disrupted supply chain, heightened unemployment and many other economic factors.
This means that results could change at any time, and the forecasted impact of risk considerations is the best estimate based on the information available as of today's date.
Additional information concerning risk factors and cautionary statements are available in our most recent SEC filings and the most recent company 10-K.
I'll now hand it over to our CEO, Ron Lombardi.
Ron?
Ronald M. Lombardi - Chairman, President & CEO
Thanks, Phil.
Let's start on Slide 5.
Last quarter, we were experiencing the very early innings of the COVID-19 pandemic.
At the time, we outlined several factors our organization began focusing on in real time to adapt to the changing environment.
As a result of these actions, I'm pleased to report a solid Q1 earnings result and better-than-expected revenues.
This is a testament to our preparedness and the strategy that we outlined.
For starters, our long-term strategy continues to work.
Our mission to provide consumers brands they know and trust is unwavering.
Even with the challenging environment being experienced due to COVID-19, our consumers continue to turn to our leading brands to meet their health care needs.
Second, our robust continuity plans continue to have us well positioned to service our retail partners.
Our investments in selecting the right manufacturing partners and maintaining ample inventory has paid off in this tight supply environment.
Third, embracing our company culture of leadership, trust, change and execution, has paid off in a big way.
It's allowed us to be agile marketers, pivoting quickly to efforts that optimize our brands in this very unique environment.
The end result is that we are winning and growing channels like e-commerce, and our portfolio continues to be well positioned for the long term.
And finally, our strong operating model and disciplined capital strategy continue to reward stakeholders.
Our strong Q1 free cash flow and industry-leading financial profile enabled further debt reduction in the quarter.
In summary, we are not sitting still.
We are learning from what is happening and adjusting our go-forward strategy in real time.
We are doing this through the guide of our proven 3-pillar strategy, which remains intact.
It drives our long-term success, and Q1 was yet another example of it.
I'll now hand it over to Chris to review Q1 financial results.
Christine Sacco - CFO
Thanks, Ron.
Good morning, everyone.
Let's turn to Slide 7 and review our high-level first quarter financial results.
Q1 revenue of $229.4 million declined 60 basis points on an organic basis versus the prior year which excludes the effects of foreign currency.
By segment, in North America, revenues were essentially flat, positively impacted by the women's health, oral care and skin categories, but offset by lower cough and cold, eye and ear care and GI shipments as categories we participate in faced declines in incidence levels and usage rates related to COVID-19.
Our international business declined in the high single digits after excluding foreign currency.
This decline was attributable to both a difficult comparison in the prior year for a number of products as well as significantly lower sales of Hydralyte in Australia as a result of COVID-19's impact to lowering both general consumer illness and activities such as athletics.
EBITDA and EPS for the first quarter grew 12% and 32%, respectively, versus the prior year.
Solid EPS growth was attributable to positive contributions across our operating expense lines as well as lower interest expense and share count from our strong free cash flow and strategic capital allocation.
Let's turn to Slide 8 for more detail around consolidated results.
As I mentioned on the prior slide, first quarter fiscal '21 revenue decreased 60 basis points versus the prior year, excluding the effects of foreign currency.
Consumption declined just over 4%.
This was better than we had anticipated back in early May, driven by strong e-commerce growth as consumers continued to shift to online purchasing.
That said, we continued to experience consumption declines in certain categories as a result of COVID-19.
As expected, these consumption declines were partially offset by inventory replenishment efforts as retailers refilled their supply following strong March consumer demand.
Total company gross margin of 58.4% increased 70 basis points versus prior year's first quarter.
We experienced early benefits from the transition to our new third-party logistics provider that was completed at the end of fiscal '20, which offset negative product mix.
For Q2, we anticipate a gross margin of approximately 58%.
Advertising and marketing came in at 12.1% of revenue, down in dollars versus the prior year as expected as we eliminated ineffective spending during the unique pandemic environment.
For the second quarter, we anticipate a more normalized rate of A&M spend of approximately 15%.
Please note this line item was previously shown as A&P, or advertising and promotion, but has been relabeled to advertising and marketing to better reflect the nature of our long-term brand-building expenses.
There have been no changes to what we are including in the numbers.
Our G&A spend for first quarter fiscal '21 was approximately $20 million or just under 9% of revenue, down from the prior year, owing to disciplined cost management and lower cost resulting from the current environment.
For Q2, we anticipate G&A expense of approximately $21 million.
Last, as stated on the prior page, EPS grew approximately 32% versus the prior year.
Lower operating costs, lower interest expense and lower share count were all factors to growth.
For Q2, we expect interest expense to approximate $21 million and a corporate tax rate of around 25%.
Now let's turn to Slide 9. In the first quarter, we generated $72.6 million in free cash flow, which represents over 40% growth versus the prior year, driven in part by the timing associated with strong retailer reorders placed in April following the March consumption spike.
For Q2, we would anticipate free cash flow below the prior year as we invest in CapEx of approximately $10 million.
Despite this, total free cash flow for the first half fiscal '21 is expected to exceed that of the prior year.
In the first quarter, we continue to focus on debt reduction and paid down $111 million in debt.
At June quarter end, we had approximately $1.6 billion in net debt, which equated to a leverage ratio of 4.4x.
We expect to continue to prioritize debt paydown as our primary use of free cash flow.
Lastly, we would like to remind investors of our continued focus on liquidity in the current environment.
We ended the quarter with over $50 million in cash on hand with ample access to our revolving credit line of well over $100 million.
And with that, I'll turn it back to Ron.
Ronald M. Lombardi - Chairman, President & CEO
Thanks, Chris.
Let's turn to Slide 11 to recap what we've seen so far this year.
As I touched on earlier, despite the uncertainty caused by COVID-19, we are pleased with the plan we implemented and our resulting Q1 performance to date.
There are a number of important factors shown here, each of which underpin the financial results Chris just touched on.
We continue to prioritize putting our employees' safety first through various proactive measures.
We have numerous manufacturing partners which are all operating in a similar capacity.
All of these employees are the enablers to our success.
We are proud of how our team members have adapted well to this volatile environment and thank them for their continued commitment.
In the middle of the slide is our supply chain.
We've continued to work with our third-party partners closely on continuity of supply.
Although dynamic, we continued to avoid any material out-of-stock positions at retail.
The results of this is continued and reliable inventory supply, an engaged workforce and committed partners, enabling us to maintain superior service levels with our retail partners.
In doing so, we have set ourselves up for both short- and long-term success.
Now let's turn to Slide 12 for an update around our brand-building efforts.
Investing in our leading portfolio of brands remains the #1 principle in our 3 pillar strategy.
Our leading brands have heritage and connections with consumers.
They are also diversified, which positions us well to navigate the impact of COVID-19 as we realized in Q1.
We continually invest in our key brands over the long term through a wide-ranging brand-building toolkit.
Critically, it features various efforts, which differentiates us from other brands and private label.
This playbook has not changed.
What has changed, as outlined last quarter, is where consumers are shopping as well as which categories they are using with frequency.
This is truly a unique attribute of the COVID-19 pandemic versus prior recessions.
This impacts all of our brands in unique ways.
Just over 1/4 into this new landscape, we are learning and adapting to the changes it brings for each of our brands in real time.
Where we've experienced the largest opportunities at the right end of the spectrum is from channel shifting into e-commerce.
Our early investments in this channel had us well positioned to capture growth as consumers transition to digital shopping during the pandemic.
A second opportunity our portfolio is experiencing is consumer focus on self-care at home.
Examples here include avoiding a doctor's visit and increasing focus on everyday hygiene and wellness.
Each of these factors are benefiting many of our brands shown towards the right of the slide.
We'll discuss a few of these in greater detail later on.
Towards the left, we highlight some challenges we are navigating due to COVID-19.
Many activities remain at suppressed levels, including time spent outdoor, travel and sports activities.
Furthermore, less time spent with people means less overall illness, which is impacting certain brands such as Hydralyte during Australia's winter season.
We've also seen reduced convenience channel traffic temporarily impact incremental to-go purchases like Clear Eyes Pocket Pal and powdered analgesics.
Despite these category challenges, our brands maintain leading positions and many had actually expanded share in the impacted categories.
An example here is Nix.
As the head lice category is currently declining due to children not in school or attending summer camps, our brand has expanded share through our ongoing brand building efforts.
With a wide range of impacts, it remains critical that we continually adapt to the changing conditions.
We are doing just that by allocating investments to the opportunities we have identified here.
Let's turn to Slide 13 to discuss some examples.
As seen on the previous slide, our diverse portfolio positions us to do well even in this challenging environment.
Our marketing efforts have moved rapidly to target the shifting needs of consumers and how best to connect with them in a pandemic world.
The page here shows just a few of the many new initiatives that kicked off recently.
On the left of the slide is Compound W. We are focused on expanding our leading position with Compound W by using marketing that reminds consumers of the ability to treat warts rapidly at home.
We believe this message and our brand's efficacy is resonating with consumers, further expanding our #1 market position.
In the middle of the page is Clear Eyes.
We had several new messages from the brand since the pandemic began.
Most recently, we are activating digital efforts focused on at-home usage and the feel-good benefit of having Clear Eyes for video calls.
The results are positive.
We're seeing higher-than-average click-through rates on Google, and our brand remains as resilient as ever.
The last example we have here is BC & Goody's.
These brands, which are concentrated in the Southeast, historically focused marketing efforts in sponsorship activities like Southern League Baseball and NASCAR.
With these events abbreviated or temporarily suspended, we reallocated our spending into various digital opportunities.
2 examples shown here are a refresh of our web pages and marketing of new products like the recently launched Goody's Hangover.
In summary, we are quickly identifying opportunities like the ones discussed here through consumer insights.
From there, our nimble marketing strategy looks to address the shifting consumer habits.
It's all part of our brand-building playbook that is built for long-term success.
Now let's turn to Slide 14 for an update on our e-commerce business.
Investments in e-commerce have meaningfully paid off as we were able to successfully engage and transact with consumers as their spending patterns shifted online.
These investments began several years ago as we invested in digital content and bringing external resources in-house.
E-commerce traffic continues to increase.
And as a result of these actions, we believe our market shares are actually above our average brick-and-mortar share in many categories.
Our established business is a leader in e-commerce, consumer health care and poised to continue benefiting from the growing interest in the channel.
In Q1, consumers increased online purchasing with the goal for many to minimize person-to-person contact during the pandemic.
E-commerce grew triple digits and now accounts for over 10% of our total retail sales with no signs of slowing.
This growth is broad-ranging across many major retail partners, but also does not include omnichannel solutions like click and collect, which have also seen impressive growth.
But we aren't sitting still.
We continue to reallocate investments into this opportunity.
Our 3 largest brands in the e-commerce channel are shown on the right side of the slide.
Each of the brands, Summer's Eve, Monistat and DenTek, have a unique strategy that continued to build successful momentum for each in Q1.
For Summer's Eve, consumers are at home more than ever.
They are exercising at home as well.
We've, therefore, refocused marketing efforts around home workouts and highlight our recently launched Summer's Eve Active products.
For DenTek, we recently launched a Beyond Brushing campaign that reminds consumers the benefits of a broad oral health care routine.
Beyond Brushing reminds consumers the benefits of flossing, dental guards and other medical devices for self-care.
It's early, but the campaign is resonating with consumers as they shop online and elsewhere.
Last, for Monistat, we are reminding home shopping consumers about quick and easy shipping to the home.
Effective advertising has successfully reminded consumers of Monistat's largely superior proposition to an in-person doctor's visit.
As a result, we are seeing a doubling of visits to our monistat.com website.
As consumers research the category, these digital investments deepen the incidence association with Monistat, consistent with our long-term strategy.
In summary, by being early and actively investing in the e-commerce channel, our brands are winning.
As the pandemic shifts consumer preferences, this provides a great positioning for our brands to benefit.
Now let's turn to Slide 16 to discuss our outlook.
One quarter into fiscal '21, we are off to a solid start for the year, thanks to our business strategy and execution.
By continuing to execute our proven strategy and focusing on our leading brands, we are well positioned to continue to weather the storm.
So the second quarter, we anticipate revenue of $225 million or more.
Within this outlook, we expect consumption to decline low to mid-single digits due to certain categories that are being affected by COVID-19.
Despite this challenge, our brands continue to hold leading positions, and many have expanded share in these declining category cases.
Most importantly, our investments continue to position these brands for the long-term growth when categories return to more normalized levels.
Our assumption also includes a modest inventory reduction expectation at retail.
Over the last month, heightened week-to-week consumption variability has declined.
As a result, we believe certain channels and retail partners may begin to adjust their inventory levels to reflect this more stable performance.
We also anticipate EPS of $0.70 or more in Q2.
Our focus on cost management efforts, along with the benefit of our capital allocation strategy and debt reduction, is expected to more than offset the anticipated Q2 revenue decline compared to the prior year.
Last, our strong and stable free cash flow remains the company's strength.
Free cash flow is expected to increase for the first half versus prior year and as always, we intend to execute a disciplined capital allocation strategy with a near-term focus on debt reduction to drive shareholder value.
With that, I'll open it up for questions.
Operator?
Operator
(Operator Instructions) Our first question comes from Steph Wissink with Jefferies.
Stephanie Marie Schiller Wissink - Equity Analyst and MD
Thanks for all the detail, Ron and Chris.
Very helpful.
I want to just unpack 3 areas.
Chris, the first one is for you, it's on the A&M, Advertising and Marketing.
I think you mentioned Q2 at 15%, but it did look like you banked a little bit of value in Q1.
How should we be thinking about how you plan to use that value?
Or do you think you would just drop that through to the bottom line and that's net benefit for the year?
Christine Sacco - CFO
Yes, Steph, I think the way we think about A&P, obviously, can be impacted by timing; in this COVID environment, very fluid.
And when I think about A&P, you'll recall in Q4, our gross margin came in higher than anticipated.
And as we always say, looking to maintain EBITDA margins in the mid-30s, we invested that additional gross margin back into A&P in Q4.
So as I look to the step-up for Q2, obviously, in A&P from Q1, to more normalized levels of about 15%, you're right, year-over-year, down slightly.
But when I think about Q4 and Q1, Q2 combined, more in line with our normalized rate of around 14% to 16%.
So it can fluctuate.
Right now, we're anticipating at about 15% for the quarter.
And I think we feel good about that number for Q2.
Stephanie Marie Schiller Wissink - Equity Analyst and MD
Okay.
And then, Ron, a question for you.
You mentioned a benefit of inventory replenishment in the quarter.
But also your comments at the end of your prepared remarks talked about potential destocking again.
Where are we along that continuum of normalizing to consumption?
Do you anticipate we're going to continue to see a headwind from destocking over the next several quarters?
Or are we nearing that point of recalibration?
Ronald M. Lombardi - Chairman, President & CEO
Yes.
So first of all, Steph, retailer inventory destocking is driven by each retailer's individual performance and their objectives and goals.
So it's tough for us to answer that for them.
But what we did call out in our second quarter outlook is that we're seeing signs of retailers beginning to make adjustments already.
So for example, in July, we've received orders from retailers that have extended delivery dates as they begin to adjust their inventory levels on hand while still trying to protect in-stock levels.
So it's something that we think is going to continue for a while through the second quarter as each retailer begins to take stock of their performance and objectives in response to those.
Stephanie Marie Schiller Wissink - Equity Analyst and MD
Okay.
And then last one for us is just on the allowance for doubtful accounts.
It was up almost 2x as a percent of receivables in the quarter versus the prior year.
It was up a bit from Q1.
So I'm just curious if you can talk a little bit about the quality of your receivables.
Are some of the new channels that you're distributing into a bit higher-risk?
How should we think about reading that relative to the receivables balance?
Christine Sacco - CFO
Yes, Steph, no change in the quality of our receivables.
That's a balance sheet account, so it's really impacted by timing.
There's been no change to the P&L impact of any of the items that would relate to an allowance.
It's been consistent in terms of terms with customers and whatnot.
And so the timing of when we clear those impacts that number, and that's the only variability for this period over others.
Operator
Our next question comes from Rupesh Parikh with Oppenheimer.
Rupesh Dhinoj Parikh - MD & Senior Analyst
So I guess I wanted to start with the question just on M&A.
Just given some of the changing consumer behavior you've seen out there related to COVID, do you see any new opportunities on the M&A front?
And I'm just curious what you're seeing out there right now.
Ronald M. Lombardi - Chairman, President & CEO
Yes.
So first of all, the place we always start in terms of evaluating M&A opportunity, Rupesh, is a brand position in the landscape that they compete in.
We look for #1 brands.
Brands that can be successful over the long term have innovation and new product opportunities.
So the COVID-19 environment really hasn't changed the screening, and we don't think has changed the positioning of categories long term that we would be interested in.
Rupesh Dhinoj Parikh - MD & Senior Analyst
Okay.
Okay.
Great.
And then from a consumption perspective.
So that was helpful color just in terms of what you guys are expecting for Q2.
But if this is the right level of behavior we see, I don't know, for a few more quarters, is that how you guys are thinking about maybe the consumption declines that you could see in the current environment?
Ronald M. Lombardi - Chairman, President & CEO
Yes.
Rupesh, I think it's still too early to tell what's going to happen in the impacted categories out in our Q3 and Q4 at this point, which is why we're only getting an outlook for Q2, right?
Things are still changing quickly and fairly dynamically.
So it's too soon to tell.
Rupesh Dhinoj Parikh - MD & Senior Analyst
Okay.
Great.
And maybe just one last question.
Just on destocking, in terms of where you guys think you could see the pressure going forward, is it any different than what you've seen in the past?
Or is it really the same channels that have been -- that have struggled that you would expect to see the continued inventory adjustments?
Ronald M. Lombardi - Chairman, President & CEO
We would expect it to be fairly consistent with what we've realized over the last year, 1.5 years, Rupesh.
Operator
Our next question comes from Linda Bolton-Weiser with D.A. Davidson.
Linda Ann Bolton-Weiser - Senior Research Analyst
I was wondering if you could talk about just the margin impact of your more rapid e-commerce growth.
Does that actually increase your gross margin, but adds to SG&A.?
So can you just give more color on that?
And then what are your top 1 or 2 biggest brands in terms of dotcom e-commerce sales on their own brand websites?
Ronald M. Lombardi - Chairman, President & CEO
Okay.
So Chris, do you want to touch on the gross margin?
And I'll talk about the brands.
Christine Sacco - CFO
Sure.
Linda, so our margins across channels -- we're channel-agnostic from a margin perspective.
So as you can see actually in our results, margin's pretty consistent despite our online sales being over 10% of our sales for the quarter.
So we manage the channel that way, manage our product offering that way.
And so no significant deviation in margins across various channels.
Ronald M. Lombardi - Chairman, President & CEO
So Linda, I think your question was around what are our 3 biggest brands that are selling online.
And I think as we -- I'm sorry, go ahead.
Linda Ann Bolton-Weiser - Senior Research Analyst
Well, no, I was just curious, in general, how much dotcom your own brand website, e-commerce activity there is.
Are you doing any?
Or is it just mostly through the Amazon of the world?
Ronald M. Lombardi - Chairman, President & CEO
It's all through our customers.
So it's through Amazon and the dotcom arms of our traditional brick-and-mortar retail partners.
We don't have any direct-to-consumer business.
Linda Ann Bolton-Weiser - Senior Research Analyst
Okay.
Great.
And then just -- I was curious about on Monistat.
I know you made some comments about your categories, but sometimes, Monistat demand is dampened when there's less antibiotic use.
And I would think with the pandemic and with social distancing, that there's less just underlying conditions requiring antibiotics.
Are you seeing that in terms of affecting the Monistat demand?
Ronald M. Lombardi - Chairman, President & CEO
So for the quarter ended June, we actually saw the total number of incidences down.
And we measure that by looking at how many prescriptions were written during that same time period.
So incident levels in totality were down, but the actual percentage of people using OTC treatments was flat to slightly up.
So in total, we actually grew share for the total vaginal yeast infection incident treatment.
And again, as we called out in the prepared remarks today, we also saw significant growth in our online business, where we've got a meaningfully bigger share online than we do even with our leading position in brick-and-mortar.
So it's, again, a great example where our long-term investments in connecting with consumers and making investments to help educate them on the incident has continued to pay off for us.
Linda Ann Bolton-Weiser - Senior Research Analyst
And then finally, can I just ask you about your balancing of your capital allocation and how you're thinking about share repurchase versus debt repayment at this point?
Ronald M. Lombardi - Chairman, President & CEO
Sure.
Chris, do you want to take that?
Christine Sacco - CFO
Sure.
So Linda, obviously, in this environment, a continued focus on liquidity, but debt paydown will continue to be our primary use of cash for now.
But as always, we'll remain flexible as conditions warrant.
And if an opportunity arises, as we've done in the past, we'll certainly take advantage of it.
Operator
Our next question comes from Joe Altobello with Raymond James.
Adam Scott Kozek - Research Associate
This is actually Adam on for Joe.
I hope you're all staying safe.
I appreciate all the color you guys gave on 1Q in terms of breaking down that organic number.
But how does consumption look more so in July?
I know you gave your expectations for low to mid consumption for the quarter.
But maybe kind of more of a breakdown of what you've seen so far, and then maybe an outlook of when you can return to that rough 2% level, although maybe some low visibility there.
Ronald M. Lombardi - Chairman, President & CEO
Sure.
So beginning very late May and into June, we began to see consumption levels stabilize, and that continued through July.
So the outlook of $225 million or more of revenue for the quarter ended September assumes that we'll continue to be at that level of consumption.
So if you compare the $225 million to last year, we're down about $13 million.
So 2/3 to roughly 3/4 of the decline year-over-year is due to that lower level of consumption, largely driven by the categories we talked about earlier today, motion fitness, lice, for example, the convenience channel.
And then the balance of it, the last 1/3 to 1/4 decline year-over-year is from an anticipated retailer inventory reduction.
Adam Scott Kozek - Research Associate
Got you.
That's very helpful.
And you guys are obviously executing quite solidly.
Maybe -- and perhaps a tough question, but why do you think maybe your products aren't seeing the same consumption lift as we've been seeing perhaps from some other HPC companies?
Ronald M. Lombardi - Chairman, President & CEO
Yes.
Again, our products are largely incident-based.
So if you don't have the illness, if you're not sick, you're not generally going to go out and buy our products.
We didn't see the same kind of pantry loading that many other categories like tableted analgesics or cold and flu category saw late in the quarter ended March and then the impact of it into the quarter ended June and then future anticipated impact.
So it starts with that.
So we didn't really see any pantry loading or delay in future purchases as a result of that.
Adam Scott Kozek - Research Associate
Great.
And if I could just piggyback, one last question here.
I know you guys have touched on capital allocation pretty thoroughly throughout the call, so I don't want to belabor the point.
But I was kind of thinking more about -- obviously, you guys mentioned your thoughts on prioritizing debt reduction.
But have you seen anything in the M&A environment that's interesting?
Have you noticed that maybe sellers are more or less likely to sell in this environment?
Even if it's not priority, I assume you guys have been keeping an eye on the market.
Ronald M. Lombardi - Chairman, President & CEO
Yes.
The M&A pipeline has been fairly active over the last year.
And surprisingly, it didn't -- it really hasn't slowed down all that much over the last 3 or 4 months, right?
Each seller has their own motivation.
And we continue to see a lot of activity out there.
And again, for us, and we've been saying this for a long time, if the right opportunity comes along, it's Chris and I's job to figure out how to get it done if we think it's meaningful for -- in terms of value creation for our shareholders.
So that will hold true going forward.
If something compelling shows up, we'll figure out how to get it done.
Operator
Our next question comes from Mitch Pinheiro with Sturdivant.
Mitchell Brad Pinheiro - Research Analyst
A couple [ordinant] questions here.
First, Ron, why is it that your market share is higher in e-commerce than in brick-and-mortar?
Is that private label?
Is that the primary factor?
Ronald M. Lombardi - Chairman, President & CEO
The competitive landscape online can be different in some categories versus brick-and-mortar.
But we don't generally see a difference in private label offerings in-store versus online, Mitch.
Really, what I'll say is, it's a testament to the heritage and the connection and the trust that's important in these categories, is that when consumers go online, it's even easier for them, if you will, to find the trusted brand that they're looking for out there.
And our continued brand building and connections with consumers plays out online, and our Q1 results are a testament to that.
Mitchell Brad Pinheiro - Research Analyst
Has there -- speaking of private label, has there been any change in any private label share in any of your categories that are noteworthy?
Ronald M. Lombardi - Chairman, President & CEO
No.
It's interesting.
The trends of the last 3 or 4 months, as we've started to understand what this COVID-19 impact means, really are the same as we've seen over the long term, which is our brands tend to outgrow the categories we compete in, and we have a history of outgrowing private label.
And it goes back to the fact that we're a marketing and brand-building company.
And every day, our employees come to work focused on providing differentiated product to any and all competitors, whether it's another branded competitor that happens to be in the category or private label so that when the consumer shows up at the shelf, there's a whole lot more difference between our products and the other offering beyond just plain price.
So that's how we think about it over the long term, is to continue to provide differentiated product and strong heritage connection and trust with consumers.
We don't think that will change going forward either.
Mitchell Brad Pinheiro - Research Analyst
Okay.
What is the breakdown of your A&M spending in terms of channel?
Is it consistent with your sort of your sales by channel?
Or is it weighted more heavily to one area?
Ronald M. Lombardi - Chairman, President & CEO
It does shift a bit over time based on opportunities or initiatives we've got going on.
But clearly, we invested at higher levels in the past couple of quarters supporting the e-commerce side of things as consumers began to run to that market.
But over time, we're going to have a multi-pronged approach to managing our brand-building and marketing, whether it's traditional TV, targeted TV, digital investments to support online purchases, whether that's search and other similar investment opportunities.
Mitchell Brad Pinheiro - Research Analyst
I don't watch a lot of TV, but I've happened to see a couple of, I guess, your ads -- your DenTek ads.
I guess it's a recent -- you mentioned, a recent campaign.
Any comments regarding that campaign?
Any near-term or recent measures of effectiveness?
Ronald M. Lombardi - Chairman, President & CEO
Sure.
First of all, what you're seeing is targeted TV.
So the DenTek Beyond Brushing campaign that started during the quarter ended June is using that as a way to identify and connect with those targeted consumers.
And if you take a look, our DenTek business was up over -- excuse me, over 10% during the quarter, and we think an important driver of that performance is the Beyond Brushing marketing campaign as well as our broad distribution and availability online.
That's another great example where consumers are looking for those trusted differentiated products online, and that was a help in driving solid growth for DenTek during the quarter.
Mitchell Brad Pinheiro - Research Analyst
Okay.
Just one last question.
Just sort of bigger picture, and I know we're still early in this COVID environment.
But has -- as you look at your business relative to this new environment, any observations?
Anything, whether you see opportunity somewhere?
Anything changed in the way you're managing your business?
Can you talk a little bit about that bigger picture?
Ronald M. Lombardi - Chairman, President & CEO
Sure.
We've talked about the benefits of our diverse business model for a long time.
And it paid out again during the quarter ended June.
When we talk about the diversity of our business, it's really on lots of different fronts.
It starts with a diverse portfolio of brands, right?
We compete in many different categories, but more importantly, we're the leader in many different subcategories, whether it's Summer's Eve, Monistat, Clear Eyes, BC & Goody's, like, the list goes on and on.
So if you take a look at our results for the first quarter, even though we had some challenges related to categories that have been impacted by COVID, like motion sickness and lice, to-go products like Clear Eyes Pocket Pal, the diversity of our portfolio allowed us to mostly offset those challenges because of the solid and strong growth online with Summer's Eve, Monistat, DenTek and other brands.
And then secondly, as I just mentioned, with the solid e-commerce, our products are broadly available across most channels, whether it's convenience, drug, grocery, mass, dollar, and now e-commerce, so that no matter where the consumer decides that they want to purchase their health care needs, our products are available, and we manage the offering in such a way that we don't have any difference in our gross margin based on where the consumer chooses to buy those products.
So we talked during the prepared remarks today a number of times around how solid our performance was and the benefits and the attributes of our strategy and our business model, and the quarter ended June's results are just a great example of how well we're positioned to do well in this challenging environment.
Operator
(Operator Instructions) Our next question comes from Carla Casella with JPMorgan.
Sarah Stuart Clark - High Yield Credit Research Analyst
This is Sarah Clark on for Carla Casella.
Just 2 quick ones for you.
In terms of cost for transportation of products, are you seeing any changes there?
We've heard from other consumer product companies that they're seeing an increase due to a shift towards airfreight to ship products.
Are you seeing any changes there on your end?
Christine Sacco - CFO
Sarah, this is --
Ronald M. Lombardi - Chairman, President & CEO
Go ahead, Chris.
Christine Sacco - CFO
Yes.
Thanks.
Sarah, so we have seen modest benefits from benefits actually from diesel and freight.
But no, for our business, just as we said, when freight costs were rising in an environment and airfreight, to your point, we've always talked about freight as a percent of our sales really not being a large component.
We always say we're not shipping dog food as an example.
So we haven't seen anything material from the transportation line other than some savings that we've got in the rates from our new warehouse location.
But from an airfreight perspective, nothing meaningful from our point of view on margin -- cost structure, yes.
Ronald M. Lombardi - Chairman, President & CEO
In addition to that, I think Chris called out earlier today that we began to see some benefits from our move to our new 3PL partner that finished up at the end of March and was our -- our sole shipping location for the U.S. during the quarter.
Sarah Stuart Clark - High Yield Credit Research Analyst
Got it.
That's super helpful.
And then apologies to go back to this, but on capital allocation, thanks for your transparency on prioritizing debt paydown and what you've been seeing in the M&A space.
We were wondering where you would feel comfortable taking leverage up to for an opportunity on the M&A side and also how you feel about your current portfolio.
Are there any potential asset sales in the future?
Or do you like all of the brands you have now?
Ronald M. Lombardi - Chairman, President & CEO
So why don't I start with the question on our portfolio, and then Chris, you can talk about leverage.
So we don't see ourselves actively managing the portfolio.
We sold the household business, I guess, it was almost 2 years ago now or 1.5 years ago, something like that.
And that was the last major change that we've seen in the portfolio.
So we feel good about the business we have and the opportunities that it's going to provide us.
Christine Sacco - CFO
Yes, Sarah, then on the leverage front, just talk about ending the quarter at 4.4x.
We continue to target a leverage ratio of 3.5x to 5x.
That said, given our consistent financial model and our consistent and strong free cash flow, for the right opportunity, would we step just above 5x?
It depends on the opportunity, right?
Obviously, qualitative factors come in as well.
But with the ability to quickly delever and get back into our range, I think it all depends on the opportunity.
But our targeted range remains at 3.5x to 5x.
Operator
I'm not showing any further questions at this time.
I would now like to turn the call back over to CEO, Ron Lombardi, for any closing remarks.
Ronald M. Lombardi - Chairman, President & CEO
Thank you, operator.
The first quarter results and our outlook are a great reminder of the resilience of our 3-pillar strategy.
We continue to invest in our leading brands.
We are generating impressive cash flow and have a proven ability for effective capital allocation that will continue to create value moving forward.
We look forward to updating you on our -- the success of our business again in a few months.
Have a great day, and thanks for joining us.
Operator
Ladies and gentlemen, this concludes today's conference call.
Thank you for participating.
You may now disconnect.